Join us for an insightful episode of BioTalk as host Rich Bendis welcomes back Rachel King, the visionary CEO of the Biotechnology Innovation Organization (BIO), bringing with her a remarkable journey spanning roles as an entrepreneur, board member, and advocate for the biotech industry.
In this engaging installment, Rachel offers a glimpse into her evolution from consulting to industry, including her role as co-founder and former CEO of GlycoMimetics, Inc. (GMI). Discover the essence of BIO, its mission, and the global perspective it brings to the biotech landscape. Delve into Rachel's advocacy role and the critical issues facing the industry today, including pricing, congressional relations, and investment challenges. Gain insights into the state of the biotech industry and Rachel's projections for both the near and long term.
Listen as we unravel the dynamic journey of Rachel King, a trailblazing leader in biotechnology, and gain a comprehensive perspective on the industry's present and future. Available now on all major podcasting platforms.
Listen now via your favorite podcasting platform:
- Apple: https://apple.co/3Eotykt
- Google: https://bit.ly/3Pb4EKm
- Spotify: https://spoti.fi/45wRwWG
- Amazon Music: https://amzn.to/483quYP
- TuneIn: https://bit.ly/45NbRXA
- YouTube Audio: https://bit.ly/3r4i3eT
Rachel King assumed the leadership of the Biotechnology Innovation Organization (BIO) as CEO on November 1, 2022. Mrs. King is co-founder and former CEO of GlycoMimetics, Inc. (GMI). Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis.
She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Mrs. King now serves on the boards of GlycoMimetics, Inc., Novavax, Inc. and the University of Maryland BioPark. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.